Background: Dihydropyridines (DHPs), a type of calcium channel blocker (CCB), are commonly prescribed for the treatment of hypertension and angina pectoris. DHPs act mainly on L-type calcium channels, essentially causing reflex tachycardia (elevated heart rate [HR]), which negatively affects cardiac function. Because T-type calcium channels in the sinoatrial node attenuate reflex tachycardia, a dual L-and T-type CCB (eg, efonidipine hydrochloride) may favorably affect cardiac pacing, thereby reducing reflex tachycardia. The effect of efonidipine as a DHP on HR deserves special consideration with regard to reflex tachycardia.
INTRODUCTION
The usefulness of long-acting calcium channel blockers (CCBs) in the treatment of cardiovascular disease (CVD) is well known. The Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial 1 (ALLHAT) showed that CCB therapy reduces the complications of hypertension.
In recent years, dihydropyridines (DHPs), a type of CCB, have commonly been prescribed for the treatment of hypertension and angina pectoris. DHPs are effective antihypertensive drugs with minimal serious side effects, [2] [3] [4] making them the most popular class of antihypertensive drugs used in Japan. All DHPs act mainly on L-type calcium channels of vessels, which respond quickly, and so may negatively affect cardiac function by activating sympathetic tone, [5] [6] [7] [8] which in turn induces an increased heart rate (HR) (reflex tachycardia). Tachycardia is a strong marker of an autonomic abnormality. It accelerates sympathetic tone and decreases vagal activity. Tachycardia, especially in the long term, 9 has been associated with an increased risk for morbidity and mortality from either cardiovascular or noncardiovascular causes in middle-aged (40-Ͻ60 years) and elderly (Ն60 years) patients with heart failure and/or ischemic heart disease. [9] [10] [11] [12] [13] Two nonselective CCBs, diltiazem and verapamil, block the L-type calcium channels in the vasculature. Therefore, they have a negative inotropic effect. They also have negative chronotropic effects, which may improve the prognosis by preventing the development of heart failure or severe systolic dysfunction. 14, 15 On the other hand, because DHPs selectively block the calcium channels in vascular smooth muscle cells, they have little negative inotropic effect. In general, DHPs that have a rapid onset of effect cause reflex tachycardia, while slow-onset and long-acting DHPs have less effect on HR. This has resulted in the widespread use of long-acting DHPs that have no acute hypotensive action.
T-type calcium channels in the sinoatrial node attenuate elevated HR by participating in cardiac pacing in the sinoatrial node cells. Therefore, L-and Ttype CCBs (eg, efonidipine hydrochloride) may favorably affect cardiac pacing, thereby reducing reflex tachycardia. Mibefradil, which does not affect L-type channels, has been described in many studies [16] [17] [18] [19] as having clinically beneficial effects on CVD. These benefits are supposedly produced by its T-type calcium channel blocking action. Unfortunately, the drug has been withdrawn from clinical use because of potential drug interactions. Efonidipine, an antihypertensive and antianginal agent with a 1,4-dihydropyridine 5-phosphonate structure, acts on both T-and L-type calcium channels, which may produce effects similar to those of mibefradil. Efonidipine has been described as having a chronotropic effect, which may suppress tachycardia. 13 Working on sinoatrial node cells by inhibiting T-type calcium channel activation or negative chronotropic effect, efonidipine prolongs the late phase-4 depolarization of the sinoatrial node action potential, which suppresses elevated HR. 13 An analysis of postmarketing surveillance of efonidipine (unpublished data, Shionogi & Co., Ltd., 2002) revealed an HR reduction in patients with a baseline HR Ͼ70 bpm. The effect of efonidipine on HR deserves additional consideration with regard to reflex tachycardia.
The aim of this pilot study was to determine whether the L-and T-type CCB efonidipine can decrease the elevated HR induced by prior treatment using traditional DHPs.
PATIENTS AND METHODS Patients
This uncontrolled, open-label pilot study was conducted at the Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine (Tokyo, Japan). Patients aged 48 to 80 years with mild to severe essential hypertension (systolic blood pressure [BP] [SBP]/diastolic BP [DBP] Ͼ140/Ͼ90 mm Hg) and angina pectoris who had been receiving antihypertensive treatment with a long-acting DHP other than efonidipine (eg, amlodipine besylate, barnidipine, benidipine hydrochloride, felodipine, manidipine hydrochloride, nifedipine) for Ͼ1 year were eligible. All of the patients were referred by physicians practicing in or near Tokyo, Japan. Verbal informed consent was provided by all patients. Pregnant, possibly pregnant, or breastfeeding women were excluded from the study. Women of childbearing age were required to use an effective method of birth control throughout the study because of possible teratogenic effects.
Methods
During an 8-week observation period, BP and HR were monitored while patients continued their existing therapy with the DHP. At week 0 (baseline), patients were switched to oral efonidipine (40-mg tablet once daily for 12 weeks) if their BP had been stable and well controlled (SBP/DBP Յ140/Յ90 mm Hg) and their HR was Ͼ80 bpm during the prior 8 weeks. Other medications remained unchanged during the study period.
BP and HR were measured by a physician every 4 weeks during the treatment period, with the patient in a sitting position after resting for Ն15 minutes.
BP was measured using a sphygmomanometer (BP-103i II; Nippon Colin, Komaki, Japan). In our study, reflex tachycardia was defined as HR Ͼ80 bpm for Ͼ2 months. Compliance was confirmed using patient interview.
Statistical Analysis
The differences in BP and HR between the observation and treatment periods were analyzed, when appropriate, using the paired Student t test. P Յ 0.05 was considered statistically significant.
RESULTS
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Figure.
Mean (SD) (A) blood pressure (BP) and (B) heart rate (HR) during the observation period (study weeks Ϫ8 to 0) and the efonidipine treatment period (study weeks 0 to 12). SBP ϭ systolic BP; DBP ϭ diastolic BP. *P Ͻ 0.01 versus week 0. † P Ͻ 0.05 versus week 0.
Mean (SD) HR during the observation period (n ϭ 18) was 94 (7) bpm. After the switch to efonidipine, it was significantly lower at 4 weeks (87 [7] bpm; P Ͻ 0.01 vs baseline), 8 weeks (86 [9] bpm; P Ͻ 0.05 vs baseline), and 12 weeks (86 [11] bpm; P Ͻ 0.05 vs baseline). Reflex tachycardia was attenuated in all patients throughout the study.
Some patients did not return to the hospital for every scheduled visit; however, all patients received the medication for the full 12-week treatment period.
DISCUSSION
Interestingly, most DHPs have been shown to cause reflex tachycardia. 10 In the present study, all the DHPs used during the observation period were long-acting agents that caused reflex tachycardia. Efonidipine caused no reflex tachycardia throughout the treatment period, while providing the same excellent antihypertensive effect as the other DHPs used during the observation period. This lack of reflex tachycardia with efonidipine may be due to its T-type calcium channel blocking action.
The favorable results produced by efonidipine in this study must be interpreted carefully because the study was conducted with a small number of patients. Although the HR was decreased with efonidipine, it is not clear whether this decreased HR is clinically significant. Additional studies using a control group and random allocation to treatment are needed. The impact of efonidipine on morbidity and mortality must be more closely examined in a long-term follow-up study of its efficacy and tolerability using a larger number of patients with hypertension or angina pectoris.
CONCLUSIONS
In this study of a small sample of patients with mild to severe essential hypertension and angina pectoris, efonidipine was as effective as other DHPs. Moreover, the drug attenuated the reflex tachycardia that occurred with other DHPs.
